cagrilintide and tirzepatide combination clinical trial Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Cagrilintide tirzepatide with cagrilintide cagrilintide tirzepatide

Conclusions Through the action of BPC-157 at doses of 10 g/kg, 1 g/kg, 100 ng/kg, and 10 ng/kg, healing of the vesicovaginal fistula in rats occurs, indicating that BPC-157 has a very strong protective effect by alleviating tissue damage and structural abnormalities caused by injury

doi:10.1002/jor.21107 Evidence-Base Disclosure The published evidence base for BPC-157 consists predominantly of preclinical research animal models (often rats or mice) and in vitro cell-culture experiments

Across these models researchers have reported faster organisation of repair tissue, improved structural recovery, and enhanced fibroblast activity in injured animals, which together form the basis of the compounds widely studied regenerative profile

And like you say, the B12 might not be the cause

Lyophilized peptides lack the aqueous environment required for rapid hydrolysis, making them far more forgiving during accidental temperature excursions

WithCare Clinic offers personalized B-12 treatments that can be tailored to your specific needs